PuSH - Publikationsserver des Helmholtz Zentrums München

Brand, P. ; Beckmann, H.* ; Maas Enriquez, M.* ; Meyer, T.* ; Müllinger, B.* ; Sommerer, K.* ; Weber, N. ; Weuthen, T.* ; Scheuch, G.*

Peripheral deposition alpha1-protease inhibitor using commercial inhalation devices.

Eur. Respir. J. 22, 263-267 (2003)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Patients with hereditary α1‐proteinase inhibitor (α1‐PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, α1‐PI replacement therapy via inhalation may be a more convenient and effective therapy than the intravenous administration of the drug. In order to optimise this treatment approach, lung deposition of inhaled radiolabelled α1‐PI (Prolastin®) was studied using four different commercial inhalation devices (PARI‐LC Star®, HaloLite®, and AKITA® system in combination with LC Star® and Sidestream®) in six patients with α1‐PI deficiency and mild-to-severe chronic obstructive pulmonary disease. The time required to deposit 50 mg of the Prolastin® (5% solution) in the lung periphery was used as a measure for the efficiency of delivery. The time was calculated from measurements of total and peripheral lung deposition of the radiolabelled α1‐PI. This time was shortest for the AKITA® system (18–24 min) and significantly higher for the PARI‐LC Star® (44 min) and the HaloLite® (100 min). The higher efficiency of drug delivery using the AKITA® system is due to the fact that this device controls breathing patterns, which are optimised for each patient individually.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Inhalation; Inhalation devices; alpha1-protease inhibitor; Replacement therapy
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Zeitschrift European Respiratory Journal
Quellenangaben Band: 22, Heft: 2, Seiten: 263-267 Artikelnummer: , Supplement: ,
Verlag European Respiratory Society
Verlagsort Sheffield
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)